GO
Loading...

Roche Holding AG

More

  • March 27- Ohr Pharmaceutical Inc said its experimental eye drug failed the main goal in a mid-stage study as a combination therapy, sending the company's shares plunging 64 percent in premarket trading on Friday. The study tested the eye-drop solution, OHR-102, in combination with Roche Holding AG's injectable eye drug Lucentis, in patients with the wet...

  • March 27- Ohr Pharmaceutical Inc said its experimental eye drug failed the main goal in a mid-stage study as a combination therapy, sending the company's shares down 21 percent in premarket trading on Friday.

  • NEW YORK, March 22- As the dollar surged in the last 12 months, David Marcus, head of the Evermore Global Value fund, steadily increased his stake in Europe. Demand for a way to hedge currency exposure while investing in Europe helped the WisdomTree Europe Hedged Equity Fund bring in $5.3 billion in new assets over the first two months of the year, the most of any equity...

  • March 20- An experimental drug from Biogen Idec Inc became the first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment. Biogen is entering a field littered with...

  • Arrowhead buys Novartis' RNAi portfolio Thursday, 5 Mar 2015 | 7:34 AM ET

    March 5- Arrowhead Research Corp said it acquired Novartis AG's RNAi assets to fortify its position in the field of gene therapy that aims to wipe out disease-causing proteins. Novartis is eligible to receive $25 million in Arrowhead shares within 30 days, which would make it the second-largest shareholder based on Arrowhead's market value on Wednesday.

  • These 10 stocks could be due for a shake-up this year Wednesday, 4 Mar 2015 | 11:02 AM ET
    Exxon Mobil

    Data from eVestment show which stocks are poised to make a big run in 2015, based on the names institutional investors have already been trading.

  • Feb 25- The U.S. Food and Drug Administration on Wednesday approved the use of Actavis Plc's antibiotic, Avycaz, to battle drug-resistant bacteria known as superbugs. Although a number of companies including Roche Holdings AG, Tetraphase Pharmaceuticals Inc, Achaogen Inc and Cempra Inc, are developing drugs for a variety of superbugs, Gabelli& Co analyst Kevin...

  • Feb 26- Diagnostics company Corgenix Medical Corp said on Thursday U.S. health regulators had approved its rapid Ebola test for emergency use, in response to the world's worst outbreak of the virus that killed more than 10,000 so far. The company's ReEBOV Antigen Rapid Test, which involves putting a drop of blood on a paper strip and waiting for at least 15 minutes...

  • UPDATE 1-Actavis' superbug antibiotic gets U.S. approval Wednesday, 25 Feb 2015 | 7:50 PM ET

    Feb 25- The U.S. Food and Drug Administration on Wednesday approved the use of Actavis Plc's antibiotic, Avycaz, to battle drug-resistant bacteria known as superbugs. Although a number of companies including Roche Holdings AG, Tetraphase Pharmaceuticals Inc, Achaogen Inc and Cempra Inc, are developing drugs for a variety of superbugs, Gabelli& Co analyst Kevin...

  • Regeneron drug tops rivals in some vision loss cases Wednesday, 18 Feb 2015 | 5:00 PM ET
    Eye examination

    Regeneron Pharmaceuticals' top-selling eye drug, Eylea, bested Roche's Lucentis and Avastin in a U.S.-sponsored study in diabetes-related vision loss.

  • Feb 5- Pfizer Inc said it would buy Hospira Inc for about $15 billion to boost its portfolio of generic injectable drugs and copies of biotech medicines. Pfizer offered $90 per share in cash, a 39 percent premium to Hospira's closing stock price on Wednesday. Hospira shares soared 35 percent to nearly $88 on Thursday, while Pfizer was up 2.7 percent at $32.93.

  • WASHINGTON, Jan 30- The United States has proposed analyzing genetic information from more than 1 million American volunteers as part of a new initiative to understand human disease and develop medicines targeted to an individual's genetic make-up. Of that, $130 million would go to the NIH to fund the research cohort and $70 million to NIH's National Cancer...

  • European stocks end mixed, Greek banks tank Wednesday, 28 Jan 2015 | 11:34 AM ET

    European markets ended mixed on Wednesday after seesawing for much of the session, with indexes pressures by a staggering slump in Greek bank stocks.

  • NEW YORK, Jan 28- President Barack Obama's plan to put the United States at the forefront of individually tailored medical treatment should give a much-needed boost to research in the field but experts say it won't work without reforms to healthcare, including drug testing and insurance. Obama said he wanted the United States to "lead a new era of medicine, one...

  • Meet Morningstar's fund managers of the year Wednesday, 21 Jan 2015 | 5:42 PM ET
    Stock performance chart on computer screen

    Here are the fund managers Morningstar considers the best of the best.

  • Swiss large-caps lose $100B on currency move Thursday, 15 Jan 2015 | 8:45 AM ET

    The Swiss franc soared—and Swiss stocks tanked—as that country's central bank shocked markets Thursday with a move to scrap a cap against the euro.

  • US stocks end lower with crude; Alcoa reports Monday, 12 Jan 2015 | 4:08 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks dropped Monday after a second weekly loss.

  • *Foundation Medicine jumps; Roche to take majority stake. Oil prices continued their downward march and weighed on equities, with both Brent and U.S. crude down about 4 percent as Goldman Sachs slashed its short-term price forecasts and Gulf producers showed no signs of curbing output. "During this cycle, since the beginning of the precipitous selloff in the...

  • *Foundation Medicine jumps; Roche to take majority stake. Oil prices continued their downward march and helped weaken futures, with Brent down 3.8 percent to $48.20 and U.S. crude down 3.7 percent to $46.59 as Goldman Sachs slashed its short-term price forecasts and Gulf producers showed no signs of curbing output. "During this cycle, since the beginning of the...

  • *Foundation Medicine jumps; Roche to take majority stake. NEW YORK, Jan 12- U.S. stock index futures rose on Monday, after a two-week decline pushed the S&P 500 back into negative territory for the year, as investors anticipated the start of the corporate earnings season. *Alcoa is scheduled to post quarterly earnings after the closing bell, with financials JPMorgan...